Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVES: This study assessed the ability of the dual-antiplatelet therapy (DAPT) score in stratifying ischemic and bleeding risk in a contemporary percutaneous coronary intervention (PCI) population. BACKGROUND: The DAPT score is recommended by guidelines as a tool to stratify ischemic and bleeding risk. Its utility in contemporary PCI is unknown. METHODS: The study studied patients in GLOBAL LEADERS (A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation) who were free of major ischemic and bleeding events and adhered to antiplatelet strategy during the first year after PCI. The primary ischemic endpoint was the composite of myocardial infarction or stent thrombosis. The primary bleeding endpoint was Bleeding Academic Research Consortium type 3 or 5. Outcomes from 12 to 24 months after PCI were compared according to the DAPT score. RESULTS: Of 11,289 patients that were event-free after the first year, 6,882 and 4,407 patients had low (<2) and high (≥2) DAPT scores, respectively. Compared with a low DAPT score, patients with a high DAPT score had a higher rate of the composites of myocardial infarction or stent thrombosis (0.70% vs. 1.55%; p 

Original publication




Journal article


JACC Cardiovasc Interv

Publication Date





634 - 646


bleeding, dual-antiplatelet therapy score, myocardial infarction, percutaneous coronary intervention, risk stratification, ticagrelor, Acute Coronary Syndrome, Aged, Clinical Decision Rules, Clinical Decision-Making, Coronary Artery Disease, Coronary Thrombosis, Drug Administration Schedule, Dual Anti-Platelet Therapy, Female, Hemorrhage, Humans, Male, Middle Aged, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Predictive Value of Tests, Progression-Free Survival, Prospective Studies, Risk Assessment, Risk Factors, Stents, Ticagrelor, Time Factors